
We assessed the efficacy and safety of zzso a new zzso zzso B vaccine developed in zzso Eighty-one healthy volunteers (75 women, 6 zzso aged zzso zzso negative for markers for zzso B and zzso received 20 zzso of the vaccine zzso at 0, 1 and 2 zzso zzso zzso zzso at one month after dose 1; of these, zzso were zzso zzso 10 zzso zzso at one month after doses 2 and 3 was zzso and zzso zzso Geometric mean zzso of zzso in subjects who zzso were 11 zzso zzso zzso zzso and zzso zzso zzso zzso One subject developed zzso rash after the second zzso there was no other adverse zzso We conclude that this vaccine is safe and zzso providing significant protection even after two zzso 

